NIH R01 · 2024
Normalizing arginine metabolism with sepiaptein for immunostimulatory-shift ofHER2+ breast cancer
In cancer cells and the tumor microenvironment, arginine metabolism is often shunted into the pathways that produce polyamines, small polycationic metabolites essential for cell growth and immuno-suppression. Such mechanisms in part account for the refractoriness of certain types of cancers, including breast cancer, to immunotherapy. However, there is a critical gap in developing a method to correct arginine metabolism to improve the immunogenicity of breast cancer. The long-term goal of our project is to develop an adjuvant treatment to improve breast cancer immunotherapy with little side effects. Specifically, the objective of this study is to test whether sepiapterin, the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.